Clinical Ink Secures Strategic Investment from Ardan Equity and GI Partners
Clinical Ink, a global clinical trial technology company, has announced strategic investments from private equity firms Ardan Equity and GI Partners. This marks the next phase of growth for Clinical Ink as it expands its platform to meet evolving industry needs in eCOA, connected devices, and other eClinical technologies used by pharmaceutical companies and CROs. The investment includes new capital from both Ardan Equity Fund I and GI Partners Fund VI, with existing investors like GI Partners Fund V exiting their prior stakes. The partnership aims to leverage the firms' combined expertise in life sciences and healthcare technology to scale Clinical Ink's global operations and deliver innovative solutions aligned with FDA requirements. Since 2020, Clinical Ink has grown its revenue, expanded into new therapeutic areas, deepened relationships with pharmaceutical clients, and launched several differentiated products. GI Partners expressed confidence in the company’s future as it benefits from increased demand for high-quality clinical trial technology.
Topics: clinical trials healthcare technology investment partnership private equity